Overview
No overview information available.
Indication
用于治疗既往接受过含直接抗病毒药物（DAA）方案、无肝硬化或伴代偿性肝硬化（Child-Pugh A）的成人慢性丙型肝炎病毒（HCV）感染
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2022/07/21 | Phase 4 | UNKNOWN | |||
2021/10/25 | N/A | UNKNOWN | |||
2018/08/08 | Phase 4 | Completed | |||
2016/04/20 | Phase 2 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Sofosbuvir, Velpatasvir and Voxilaprevir tablets | 国药准字HJ20190061 | 化学药品 | 片剂 | 11/12/2024 | |
| Sofosbuvir, Velpatasvir and Voxilaprevir tablets | H20190061 | 化学药品 | 片剂 | 12/18/2019 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.